Paratek Pharmaceuticals, Inc.
DelistedCIK 1178711fmd_1HGY6K9VMHAA2WGZ5RTAGGE2KQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2023, 54 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | (5) | 4 | – | 0 | 13 | 17 | 17 | 47 | 130 | 160 |
| Net interest income | (0) | (1) | (1) | – | – | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | 3 | 9 | 22 | 23 |
| Gross profit | – | – | – | – | – | – | 13 | 38 | 109 | 137 |
| Research and development | 5 | 5 | 51 | 83 | 60 | 58 | 40 | 24 | 30 | 38 |
| Selling, general and administrative | – | – | – | – | – | 64 | 89 | 90 | 119 | 146 |
| Operating income | (8) | (8) | (70) | (109) | (85) | (104) | (116) | (76) | (41) | (46) |
| Interest expense | – | 1 | 1 | 3 | 5 | 11 | 16 | 20 | 17 | 18 |
| Interest and investment income | – | – | – | 1 | 1 | 3 | 4 | 2 | 0 | 1 |
| Other non-operating income (expense) | (0) | (0) | (0) | 0 | (0) | (0) | (0) | 0 | (0) | 0 |
| Income before taxes | – | (20) | (71) | (112) | (88) | (112) | (128) | (97) | (58) | (64) |
| Income tax expense | 0 | 0 | 0 | 0 | 1 | 1 | 0 | – | 1 | 0 |
| Net income from continuing operations | – | (20) | (71) | (112) | (89) | (112) | (129) | – | (59) | (64) |
| Net income | (5) | (18) | (71) | (112) | (89) | (112) | (129) | (97) | (59) | (64) |
| Net income to common shareholders | (11) | (20) | (71) | (112) | (89) | – | – | – | – | – |